Avnet YEL will operate as a specialist division to maintain its focus on IP&E profitable growth.
Stephen Wong, President of Avnet Electronics Marketing Asia added, "The acquisition of YEL is a clear demonstration of Avnet's commitment to invest in the high growth Asia components market.
On March 28, 2002, a man aged 70 years received YEL in preparation for travel to Venezuela.
On September 17, 2001, a man aged 36 years received YEL in preparation for travel to Brazil.
On October 4, 2001, a man aged 71 years received YEL and typhoid and hepatitis A vaccines in preparation for travel to Guatemala.
On February 7, 2002, a man aged 41 years received YEL and hepatitis A vaccine in preparation for travel to Venezuela.
On May 17, 2002, a boy aged 16 years received YEL in preparation for travel to South America; 23 days after vaccination, he had left-arm numbness, inability to speak, loss of right-side fine motor control, expressive aphasia, and severe dysarthria.
YEL is a live virus preparation containing 17D vaccine strain made by serial passage of wild type YF virus to attenuate neurotropic and viscerotropic properties while preserving immunogenicity (4).
The cases of neurologic disease had evidence that 17D-derived YEL was the likely cause of illness.
However, enhanced VAERS surveillance efforts alone might not detect all serious adverse events after receipt of YEL (7).
5[degrees] C) for >24 hours and illness onset [less than or equal to]30 days following receipt of YEL.